386 related articles for article (PubMed ID: 34314483)
1. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
[TBL] [Abstract][Full Text] [Related]
2. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
[TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
4. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
[TBL] [Abstract][Full Text] [Related]
5. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
6. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
7. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
8. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
[TBL] [Abstract][Full Text] [Related]
9. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
10. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
[TBL] [Abstract][Full Text] [Related]
11. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
[TBL] [Abstract][Full Text] [Related]
13. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
[TBL] [Abstract][Full Text] [Related]
16. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
17. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
18. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
Wang LY; Hu QL; Chen M; Yang C; Han B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
[No Abstract] [Full Text] [Related]
19. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
20. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
